Cost-effectiveness analysis of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Anastrozole combined with Abemaciclib is more cost-effective than Anastrozole used alone for the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Authors
- Xiaofeng Lin (ORCID: https://orcid.org/0000-0003-4802-0812)
- Zhe Huang (ORCID: https://orcid.org/0000-0001-6472-4743)
- Xiaoxi Liu (ORCID: https://orcid.org/0000-0002-1933-8613)
- Jing Wang (ORCID: https://orcid.org/0000-0003-4896-0142)
- Wei Zhao (ORCID: https://orcid.org/0000-0002-1785-2037)
- Yipeng Lan
Institutions
- Shenyang Pharmaceutical University (CN)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1186/s12962-025-00605-z
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shenyang Pharmaceutical University